The Authors’ reply We would like to thank Yalta et al 1 for their interest in our review. We share their enthusiasm for the potential metabolic benefits of sodium-glucose co-transporter 2 (SGLT-2) inhibition. We agree with Yalta et al that in patients with type 2 diabetes or heart failure, there is dysregulated fatty acid oxidation and impaired glucose uptake causing myocardial dysfunction. In this setting of restricted fuel selection and low energetic reserve, ketone bodies are a super-fuel producing Adenosine triphosphate (ATP) more efficiently than free fatty acids or glucose, which usually serve as fuels for …

中文翻译：

---

回复：Yalta 等人关于“钠-葡萄糖协同转运蛋白 2 抑制剂治疗：心力衰竭的作用机制”的通讯

作者的回复 我们要感谢雅尔塔等人 1 对我们的评论感兴趣。我们和他们一样对钠-葡萄糖协同转运蛋白 2 (SGLT-2) 抑制的潜在代谢益处充满热情。我们同意雅尔塔等人的观点，即在 2 型糖尿病或心力衰竭患者中，脂肪酸氧化失调和葡萄糖摄取受损，导致心肌功能障碍。在燃料选择受限和能量储备低的情况下，酮体是一种超级燃料，比游离脂肪酸或葡萄糖更有效地产生三磷酸腺苷 (ATP)，而游离脂肪酸或葡萄糖通常用作……的燃料。